Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

TKNO - Alpha Teknova, Inc. Последние новости | Finranks

Home

/

TKNO

A

Alpha Teknova, Inc. (TKNO)

NGM – Цена в реальном времени. Валюта: USD

3.99

+0.18 (4.72%)

При закрытии: May 12, 2026, 4:00 PM EDT

3.65

-0.34 (-8.52%)

До открытия: May 13, 2026, 4:01 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Alpha Teknova, Inc. (TKNO) Q1 2026 Earnings Call Transcript

Alpha Teknova, Inc. (TKNO) Q1 2026 Earnings Call Transcript

Alpha Teknova, Inc. (TKNO) Q1 2026 Earnings Call Transcript

Teknova Reports First Quarter 2026 Financial Results

Teknova Reports First Quarter 2026 Financial Results

First quarter 2026 total revenue was $11.1 million, up 13% over the same quarter prior year Company reaffirms 2026 revenue guidance of $42-44 million

Teknova to Report First Quarter 2026 Financial Results on May 6, 2026

Teknova to Report First Quarter 2026 Financial Results on May 6, 2026

HOLLISTER, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2026, on Wednesday, May 6, 2026, following the close of market.

Alpha Teknova, Inc. (TKNO) Q4 2025 Earnings Call Transcript

Alpha Teknova, Inc. (TKNO) Q4 2025 Earnings Call Transcript

Alpha Teknova, Inc. (TKNO) Q4 2025 Earnings Call Transcript

Teknova Reports Fourth Quarter and Full Year 2025 Financial Results

Teknova Reports Fourth Quarter and Full Year 2025 Financial Results

Full year 2025 total revenue was $40.5 million, up 7% year-over-year and in line with guidance Fourth quarter 2025 total revenue was $10.0 million, up 8% over the same quarter prior year Company provides 2026 revenue guidance of $42-44 million

Teknova to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Teknova to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

HOLLISTER, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, following the close of market.

Alpha Teknova, Inc. (TKNO) Q3 2025 Earnings Call Transcript

Alpha Teknova, Inc. (TKNO) Q3 2025 Earnings Call Transcript

Alpha Teknova, Inc. ( TKNO ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Jennifer Henry - Senior Vice President of Marketing Stephen Gunstream - President, CEO & Director Matthew Lowell - Chief Financial Officer Conference Call Participants Steven Etoch - Stephens Inc., Research Division Brendan Smith - TD Cowen, Research Division Matthew Larew - William Blair & Company L.L.C., Research Division Tollef Kohrman - Craig-Hallum Capital Group LLC, Research Division Vidyun Bais - BTIG, LLC, Research Division Presentation Operator Good day, and thank you for standing by.

Видео

No Data

There is no data to display

Пресс-релизы

Teknova Reports First Quarter 2026 Financial Results

Teknova Reports First Quarter 2026 Financial Results

First quarter 2026 total revenue was $11.1 million, up 13% over the same quarter prior year Company reaffirms 2026 revenue guidance of $42-44 million

Teknova Reports Fourth Quarter and Full Year 2025 Financial Results

26.02.2026

Teknova Reports Fourth Quarter and Full Year 2025 Financial Results

Full year 2025 total revenue was $40.5 million, up 7% year-over-year and in line with guidance Fourth quarter 2025 total revenue was $10.0 million, up 8% over the same quarter prior year Company provides 2026 revenue guidance of $42-44 million

Teknova Reports Third Quarter 2025 Financial Results

Teknova Reports Third Quarter 2025 Financial Results

Third quarter 2025 total revenue was $10.5 million, up 9% from prior year Achieves five consecutive quarters of year-over-year revenue growth Company reaffirms 2025 revenue guidance of $39-42 million

Teknova Reports Second Quarter 2025 Financial Results

Teknova Reports Second Quarter 2025 Financial Results

Second quarter 2025 total revenue was $10.3 million, up 7% from prior year Achieves four consecutive quarters of year-over-year revenue growth Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2025.